Clinical Trials Logo

Pityriasis Rubra Pilaris clinical trials

View clinical trials related to Pityriasis Rubra Pilaris.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03975153 Completed - Clinical trials for Pityriasis Rubra Pilaris

Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Start date: October 3, 2019
Phase: Phase 2
Study type: Interventional

15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.

NCT ID: NCT03485976 Completed - Clinical trials for Pityriasis Rubra Pilaris

Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Start date: May 23, 2018
Phase: Phase 2
Study type: Interventional

15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit. 5 visits in between these times and one follow up visit may be performed by secure videoconferencing.

NCT ID: NCT03342573 Completed - Clinical trials for PITYRIASIS RUBRA PILARIS

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Start date: April 1, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.